{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:19:45Z","timestamp":1783714785349,"version":"3.55.0"},"reference-count":127,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Clin Cancer Inform"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The phased framework of oncology trials is designed to ensure patient safety and conserve resources by advancing only promising therapies from early- to late-phase testing. Despite decades of refinement, overall trial success rates\u2014defined by the proportion of studies ultimately supporting regulatory approval\u2014remain low, with failures increasingly occurring in late-phase studies. These failures are often contributed to by methodological shortcomings, including suboptimal end point selection, restrictive eligibility criteria, and inefficient trial designs. Although traditional approaches to biomarker discovery, outcome validation, and eligibility refinement have yielded transformational advances, increasing molecular subclassification of tumors into rare subgroups results in the conventional drug development framework being no longer fit for purpose. Artificial intelligence (AI) offers opportunities to enhance the efficiency, precision, and patient-centeredness of oncology trials. Deep learning systems integrate and analyze large data sets to uncover complex patterns often inaccessible to conventional methods. AI has potential applications in patient-trial matching, optimization of eligibility criteria, statistical modeling of survival outcomes, and the identification of novel surrogate end points although these applications remain largely investigational and are not yet established for routine use. This scoping review provides a structured overview of AI applications in oncology trials, with emphasis on outcome selection and surrogate end point evaluation. We also highlight emerging areas with potential for immediate implementation, such as patient selection, biomarker identification and synthetic control arms, to accelerate development and enhance clinical care. However, broader harmonization is needed to ensure reproducibility, transparency, and regulatory confidence before implementation. Ultimately, early and sustained collaboration between trialists, AI developers, and regulators will be essential to ensure that AI delivers meaningful advances in the design, evaluation, and delivery of new medicines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/cci-26-00014","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:00:14Z","timestamp":1783713614000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9470-314X","authenticated-orcid":true,"given":"Rachel","family":"Woodford","sequence":"first","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia"},{"name":"Department of Experimental Cancer Medicines, The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Lord","sequence":"additional","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-6874","authenticated-orcid":true,"given":"Frank","family":"Lin","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Darlinghurst, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Papenfuss","sequence":"additional","affiliation":[{"name":"Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Marschner","sequence":"additional","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thomas","sequence":"additional","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-795X","authenticated-orcid":true,"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3689-5956","authenticated-orcid":true,"given":"Clare","family":"Scott","sequence":"additional","affiliation":[{"name":"Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, Parkville, VIC, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-7563","authenticated-orcid":true,"given":"John","family":"Simes","sequence":"additional","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Khoon","family":"Lee","sequence":"additional","affiliation":[{"name":"National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia"},{"name":"Department of Medical Oncology, St George Hospital, Kogarah, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282542"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.10.009"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.3931"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.6008"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.05.005"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2021.2011901"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/2168479016632271"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2018.08.001"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01614-0"},{"key":"e_1_3_7_11_2","volume-title":"Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products","author":"FDA","year":"2023","unstructured":"FDA: Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products. US Food and Drug Administration Guidance Document. Silver Spring, MD, US Food and Drug Administration, 2023"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8156"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0316-z"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14539"},{"key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.9.2.9","article-title":"How artificial intelligence can transform randomized controlled trials","volume":"9","author":"Lee CS","year":"2020","unstructured":"Lee CS, Lee AY: How artificial intelligence can transform randomized controlled trials. Transl Vis Sci Technol 9:9, 2020","journal-title":"Transl Vis Sci Technol"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1199"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113844"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobeha.2018.12.010"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-00376-2"},{"key":"e_1_3_7_20_2","article-title":"Synthetic data generation by artificial intelligence to accelerate research and precision medicine in hematology","author":"D'Amico S","unstructured":"D'Amico S, Dall\u2019Olio D, Sala C, et al: Synthetic data generation by artificial intelligence to accelerate research and precision medicine in hematology. JCO Clin Cancer Inform 10.1200\/CCI.23.00021","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00425-3"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00751-8"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxx069"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1235"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.125"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11081406"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.012"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i40.6207"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20178124"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4235"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf355"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31535-6"},{"key":"e_1_3_7_33_2","first-page":"743","article-title":"A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1\/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer","volume":"13","author":"Yang Y","year":"2021","unstructured":"Yang Y, Yang J, Shen L, et al: A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1\/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. Am J Transl Res 13:743-756, 2021","journal-title":"Am J Transl Res"},{"key":"e_1_3_7_34_2","article-title":"PSA\/testosterone ratio as a potential biomarker to identify early progressors of adaptive therapy in metastatic castration sensitive prostate cancer","author":"Gallaher JA","unstructured":"Gallaher JA, Gatenby RA, Brown JS, et al: PSA\/testosterone ratio as a potential biomarker to identify early progressors of adaptive therapy in metastatic castration sensitive prostate cancer. medRxiv 10.1101\/2025.05.08.25327179","journal-title":"medRxiv"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24698-1"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002240"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.11.009"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13195"},{"key":"e_1_3_7_39_2","volume-title":"Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products","author":"FDA","year":"2019","unstructured":"FDA: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. US Food and Drug Administration Guidance Document. Silver Spring, MD, US Food and Drug Administration, 2019"},{"key":"e_1_3_7_40_2","volume-title":"Enhancing the Diversity of Clinical Trial Populations\u2014Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry","author":"FDA","year":"2020","unstructured":"FDA: Enhancing the Diversity of Clinical Trial Populations\u2014Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. US Food and Drug Administration Guidance Document. Silver Spring, MD, Center for Biologics Evaluation and Research, 2020"},{"key":"e_1_3_7_41_2","first-page":"1101","volume-title":"AMIA Annual Symposium Proceedings AMIA Symposium","author":"Li Q","year":"2019","unstructured":"Li Q, He Z, Guo Y, et al: Assessing the validity of a priori patient-trial generalizability score using real-world data from a large clinical data research network: A colorectal cancer clinical trial case study. AMIA Annual Symposium Proceedings AMIA Symposium, 2019, pp 1101-1110"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03430-5"},{"key":"e_1_3_7_43_2","first-page":"641","article-title":"Review of the performance metrics for natural language systems for clinical trials matching","volume":"290","author":"Kim J","year":"2022","unstructured":"Kim J, Quintana Y: Review of the performance metrics for natural language systems for clinical trials matching. Stud Health Technol Inform 290:641-644, 2022","journal-title":"Stud Health Technol Inform"},{"key":"e_1_3_7_44_2","first-page":"203","volume-title":"AMIA Joint Summits on Translational Science Proceedings AMIA Joint Summits on Translational Science","author":"Liang JJ","year":"2017","unstructured":"Liang JJ, Tsou CH, Devarakonda MV: Ground truth creation for complex clinical NLP tasks\u2014An iterative vetting approach and lessons learned. AMIA Joint Summits on Translational Science Proceedings AMIA Joint Summits on Translational Science, 2017, pp 203-212"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2009.08.007"},{"key":"e_1_3_7_46_2","article-title":"Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board","volume":"42","author":"Lin FP-Y","year":"2024","unstructured":"Lin FP-Y, Grady JP, Napier CE, et al: Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board. J Clin Oncol 42, 2024 (suppl 16; abstr 1557)","journal-title":"J Clin Oncol"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203527"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781315137438"},{"key":"e_1_3_7_49_2","first-page":"1","article-title":"Time-to-event prediction with neural networks and Cox regression","volume":"20","author":"Kvamme H","year":"2019","unstructured":"Kvamme H, Borgan \u00d8, Scheel I: Time-to-event prediction with neural networks and Cox regression. J Machi Learn Res 20:1-30, 2019","journal-title":"J Machi Learn Res"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.6257"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.1609\/aaai.v32i1.11842"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0482-1"},{"key":"e_1_3_7_53_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1006076"},{"key":"e_1_3_7_54_2","doi-asserted-by":"publisher","DOI":"10.1145\/3627673.3679947"},{"key":"e_1_3_7_55_2","article-title":"Status of synthetic data generation for structured health data","author":"El Emam K","unstructured":"El Emam K: Status of synthetic data generation for structured health data. JCO Clin Cancer Inform 10.1200\/CCI.23.00071","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_7_56_2","article-title":"Novel generative recurrent neural network framework to produce accurate, applicable, and deidentified synthetic medical data for patients with metastatic cancer","author":"Ganguli R","unstructured":"Ganguli R, Lad R, Lin A, et al: Novel generative recurrent neural network framework to produce accurate, applicable, and deidentified synthetic medical data for patients with metastatic cancer. JCO Clin Cancer Inform 10.1200\/CCI.22.00125","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_7_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae325"},{"key":"e_1_3_7_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.015"},{"key":"e_1_3_7_59_2","article-title":"Framework for the use of external controls to evaluate treatment outcomes in precision oncology trials","author":"Siu DHW","unstructured":"Siu DHW, Lin FPY, Cho D, et al: Framework for the use of external controls to evaluate treatment outcomes in precision oncology trials. JCO Precis Oncol 10.1200\/PO.23.00317","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_7_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105331"},{"key":"e_1_3_7_61_2","article-title":"Opportunities and challenges of synthetic data generation in oncology","author":"Jacobs F","unstructured":"Jacobs F, D'Amico S, Benvenuti C, et al: Opportunities and challenges of synthetic data generation in oncology. JCO Clin Cancer Inform 10.1200\/CCI.23.00045","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_7_62_2","article-title":"Evaluating the utility and privacy of synthetic breast cancer clinical trial data sets","author":"El Kababji S","unstructured":"El Kababji S, Mitsakakis N, Fang X, et al: Evaluating the utility and privacy of synthetic breast cancer clinical trial data sets. JCO Clin Cancer Inform 10.1200\/CCI.23.00116","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_7_63_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043497"},{"key":"e_1_3_7_64_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-019-0793-0"},{"key":"e_1_3_7_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1589"},{"key":"e_1_3_7_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.70129"},{"key":"e_1_3_7_67_2","first-page":"530","volume-title":"AMIA Annual Symposium Proceedings AMIA Symposium","author":"Neehal N","year":"2023","unstructured":"Neehal N, Anand V, Bennett KP: Framework for research in equitable synthetic control arms. AMIA Annual Symposium Proceedings AMIA Symposium, 2023, pp 530-539"},{"key":"e_1_3_7_68_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S242097"},{"key":"e_1_3_7_69_2","doi-asserted-by":"publisher","DOI":"10.3102\/1076998607306078"},{"key":"e_1_3_7_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2190"},{"key":"e_1_3_7_71_2","volume-title":"International Conference on Artificial Intelligence and Statistics","author":"Norcliffe A","year":"2023","unstructured":"Survivalgan: Generating time-to-event data for survival analysis, in Norcliffe A, Cebere B, Imrie F, et al (eds): International Conference on Artificial Intelligence and Statistics. PMLR, 2023"},{"key":"e_1_3_7_72_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1554"},{"key":"e_1_3_7_73_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3627-6"},{"key":"e_1_3_7_74_2","article-title":"RCT-Twin-GAN generates digital twins of randomized control trials adapted to real-world patients to enhance their inference and application","author":"Thangaraj PM","unstructured":"Thangaraj PM, Shankar SV, Oikonomou EK, et al: RCT-Twin-GAN generates digital twins of randomized control trials adapted to real-world patients to enhance their inference and application. medRxiv 10.1101\/2023.12.06.23299464","journal-title":"medRxiv"},{"key":"e_1_3_7_75_2","first-page":"233","article-title":"Transforming two decades of ePR data to OMOP CDM for clinical research","volume":"264","author":"Lima DM","year":"2019","unstructured":"Lima DM, Rodrigues-Jr JF, Traina AJM, et al: Transforming two decades of ePR data to OMOP CDM for clinical research. Stud Health Technol Inform 264:233-237, 2019","journal-title":"Stud Health Technol Inform"},{"key":"e_1_3_7_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_3_7_77_2","doi-asserted-by":"publisher","DOI":"10.1145\/3422622"},{"key":"e_1_3_7_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocx019"},{"key":"e_1_3_7_79_2","doi-asserted-by":"publisher","DOI":"10.2196\/35734"},{"key":"e_1_3_7_80_2","article-title":"Validity and efficiency of progression-free survival-2 as a surrogate end point for overall survival in advanced cancer randomized trials","author":"Woodford R","unstructured":"Woodford R, Zhou D, Kok PS, et al: Validity and efficiency of progression-free survival-2 as a surrogate end point for overall survival in advanced cancer randomized trials. JCO Precis Oncol 10.1200\/PO.23.00296","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_7_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102283"},{"key":"e_1_3_7_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2022.100445"},{"key":"e_1_3_7_83_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33240"},{"key":"e_1_3_7_84_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13190-w"},{"key":"e_1_3_7_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01981-2"},{"key":"e_1_3_7_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00408-3"},{"key":"e_1_3_7_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(21)00215-6"},{"key":"e_1_3_7_88_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4475-6"},{"key":"e_1_3_7_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105509"},{"key":"e_1_3_7_90_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004107"},{"key":"e_1_3_7_91_2","doi-asserted-by":"publisher","DOI":"10.1109\/TBME.2019.2909027"},{"key":"e_1_3_7_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0368-0"},{"key":"e_1_3_7_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43588-021-00083-2"},{"key":"e_1_3_7_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1170"},{"key":"e_1_3_7_95_2","article-title":"Validation of predictive analyses for interim decisions in clinical trials","author":"Avalos-Pacheco A","unstructured":"Avalos-Pacheco A, Ventz S, Arf\u00e8 A, et al: Validation of predictive analyses for interim decisions in clinical trials. JCO Precis Oncol 10.1200\/PO.22.00606","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_7_96_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15050533"},{"key":"e_1_3_7_97_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.120.000028"},{"key":"e_1_3_7_98_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-022-01923-5"},{"key":"e_1_3_7_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-02006-1"},{"key":"e_1_3_7_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01102-x"},{"key":"e_1_3_7_101_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34085"},{"key":"e_1_3_7_102_2","article-title":"Predictions as surrogates: Revisiting surrogate outcomes in the age of AI","author":"Ji W","unstructured":"Ji W, Lei L, Zrnic T: Predictions as surrogates: Revisiting surrogate outcomes in the age of AI. arXiv 10.48550\/arXiv.2501.09731","journal-title":"arXiv"},{"key":"e_1_3_7_103_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi6000"},{"key":"e_1_3_7_104_2","article-title":"PPI++: Efficient prediction-powered inference","author":"Angelopoulos AN","unstructured":"Angelopoulos AN, Duchi JC, Zrnic T: PPI++: Efficient prediction-powered inference. arXiv 10.48550\/arXiv.2311.01453","journal-title":"arXiv"},{"key":"e_1_3_7_105_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0909"},{"key":"e_1_3_7_106_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780080407"},{"key":"e_1_3_7_107_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv333"},{"key":"e_1_3_7_108_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181b9c602"},{"key":"e_1_3_7_109_2","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/1.1.49"},{"key":"e_1_3_7_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.43"},{"key":"e_1_3_7_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2020.103406"},{"key":"e_1_3_7_112_2","volume-title":"Good Machine Learning Practice for Medical Device Development: Guiding Principles","author":"FDA","year":"2021","unstructured":"FDA: Good Machine Learning Practice for Medical Device Development: Guiding Principles. US Food and Drug Administration Guidance Document. Silver Spring, MD, US Food and Drug Administration, 2021"},{"key":"e_1_3_7_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30186-2"},{"key":"e_1_3_7_114_2","doi-asserted-by":"publisher","DOI":"10.1148\/ryai.220028"},{"key":"e_1_3_7_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.artint.2022.103839"},{"key":"e_1_3_7_116_2","doi-asserted-by":"publisher","DOI":"10.3390\/e23010018"},{"key":"e_1_3_7_117_2","article-title":"A unified approach to interpreting model predictions","author":"Lundberg S","unstructured":"Lundberg S: A unified approach to interpreting model predictions. arXiv 10.48550\/arXiv.1705.07874","journal-title":"arXiv"},{"key":"e_1_3_7_118_2","article-title":"Towards the science of security and privacy in machine learning","author":"Papernot N","unstructured":"Papernot N, McDaniel P, Sinha A, et al: Towards the science of security and privacy in machine learning. arXiv 10.48550\/arXiv.1611.03814","journal-title":"arXiv"},{"key":"e_1_3_7_119_2","doi-asserted-by":"publisher","DOI":"10.2196\/27767"},{"key":"e_1_3_7_120_2","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooaa002"},{"key":"e_1_3_7_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2019.05.018"},{"key":"e_1_3_7_122_2","article-title":"Artificial intelligence tool for optimizing eligibility screening for clinical trials in a large community cancer center","author":"Beck JT","unstructured":"Beck JT, Rammage M, Jackson GP, et al: Artificial intelligence tool for optimizing eligibility screening for clinical trials in a large community cancer center. JCO Clin Cancer Inform 10.1200\/CCI.19.00079","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_7_123_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2580"},{"key":"e_1_3_7_124_2","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2022.1030194"},{"key":"e_1_3_7_125_2","doi-asserted-by":"publisher","DOI":"10.2196\/50216"},{"key":"e_1_3_7_126_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081554"},{"key":"e_1_3_7_127_2","volume-title":"Principles for the Responsible Use of Artificial Intelligence in Oncology","author":"ASCO","year":"2025","unstructured":"ASCO: Principles for the Responsible Use of Artificial Intelligence in Oncology. Alexandria, VA, ASCO, 2025"},{"key":"e_1_3_7_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103656"}],"container-title":["JCO Clinical Cancer Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/CCI-26-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:00:19Z","timestamp":1783713619000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/CCI-26-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1200\/CCI-26-00014"],"URL":"https:\/\/doi.org\/10.1200\/cci-26-00014","relation":{},"ISSN":["2473-4276"],"issn-type":[{"value":"2473-4276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600014"}}